Here, we briefly describe the clinical efficacy of PI3K inhibitors, then discuss the mechanisms and management of the more common unusual toxicities seen with these agents.
I. Brian Greenwell, MD
Advertisement
Articles by I. Brian Greenwell, MD
Advertisement
Latest Updated Articles
- PI3K Inhibitors: Understanding Toxicity Mechanisms and Management
Published: November 15th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
4
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
5
